Puma Biotechnology (PBYI)
(Delayed Data from NSDQ)
$3.49 USD
-0.04 (-0.99%)
Updated Jun 10, 2024 04:00 PM ET
After-Market: $3.50 +0.01 (0.29%) 7:58 PM ET
3-Hold of 5 3
A Value A Growth D Momentum A VGM
Brokerage Reports
0 items in cart
Puma Biotechnology, Inc. [PBYI]
Reports for Purchase
Showing records 21 - 40 ( 227 total )
Company: Puma Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
Company: Puma Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Puma Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
3Q23 Results; Nerlynx U.S. Sales Flat QoQ But Expected to Increase in 4Q23; Alisertib Phase 2 Trial to Initiate in 4Q23
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Puma Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
Company: Puma Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Puma Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
Company: Puma Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Puma Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
Alisertib Combination Data Presented at AACR-NCI-EORTC
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Puma Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
Alisertib Granted Orphan Drug Designation in Small Cell Lung Cancer
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Puma Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
Company: Puma Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Puma Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
Company: Puma Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Puma Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
2Q23 Results; Nerlynx Sales Beat Estimates; Phase 2 Trial of Alisertib in SCLC Expected to Start in 2H23
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Puma Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
Company: Puma Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Puma Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Puma Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Puma Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
Biomarker Data for Alisertib Presented at ASCO 2023
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Puma Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department